



# ACCADEMIA MEDICA DI ROMA

mercoledì 31 gennaio 2024, ore 16.00  
Auditorium Prima Clinica Medica  
Policlinico Umberto I, viale del Policlinico 155, Roma

La conferenza potrà essere seguita in presenza presso la sede sopra descritta oppure in streaming sulla piattaforma Zoom utilizzando il seguente link

<https://uniroma1.zoom.us/j/92312414393?pwd=cDM2bTZ3VldoWEFjSnNjNjR6bmtJdz09>

(Meeting ID: 923 1241 4393; Passcode: accademia)

## Marco A. Cassatella

Patologia generale, Università di Verona

*Parlerà sul tema:*

**“Learning about slan<sup>+</sup>-monocytes while working on neutrophils, and viceversa”**

*La S.V. è invitata ad intervenire.*

L'ACCADEMICO SEGRETARIO  
ANTONIO MUSARO'

IL PRESIDENTE  
VINCENZO BARNABA

**Il certificato di partecipazione verrà rilasciato solo in presenza**

## **Learning about slan<sup>+</sup>-monocytes while working on neutrophils, and vice-versa**

**Marco A. Cassatella, Dipartimento di Medicina, Sezione di Patologia Generale, Università di Verona**

Peripheral monocytes in humans are conventionally divided into classical (CL, CD14<sup>++</sup>CD16<sup>-</sup>), intermediate (INT, CD14<sup>++</sup>CD16<sup>+</sup>) and non-classical (NC, CD14<sup>dim/-</sup>CD16<sup>++</sup>) cells, based on their expression levels of CD14 and CD16. Notably, a major fraction of the NC-monocytes has been shown to express the 6-sulfo LacNAc (slan) antigen, a feature that enables for them the name of “slan<sup>+</sup>-monocytes”. My dissertation will summarize what is currently known about the biology of slan<sup>+</sup>-monocytes, why it is worth pursuing the investigation on these cells, and how the research of my lab focused on neutrophils has often been interconnected with that on the slan<sup>+</sup>-monocytes.

## Marco A. Cassatella's *curriculum vitae*

ORCID: **0000-0001-7824-1806**

- 2001 – current: **Professor**, Department of Medicine, General Pathology Section (Verona University, Italy)
- 2000-2016 **Coordinator of the PhD program** in “Molecular and Cellular Biology and Pathology” and then in “Inflammation, Immunity and Cancer” at the Verona University, Italy;

“**Telethon Scientific Committee**” member (2007-2011)

**CTS Member** of Associazione della Ricerca contro il cancro (AIRC) (2018-2023)

**ESCI Councillor** (2002-2003)

**Society of Leukocyte Biology (SLB) Councillor** (USA) (2010-2014)(2014-2015)

**Italian Society of Immunology (SIICA): Councillor** (2000-2004, 2005-2008); **President-elect** (2017-2021); **President** (2021-2024)

### MEMBERSHIPS OF SCIENTIFIC SOCIETIES:

**SIICA, SLB, AAI, NIBIT, H1 connect** (previously **F1000** and **Faculty Opinion**)

<https://connect.h1.co/member/8233555563391168>

2021 **SLB Honorary Member** (SLB) (<https://slb.memberclicks.net/honorary-life-members>)

2017 **Bonazinga/Legacy Award** from the Society of Leukocyte Biology (SLB) (<https://slb.memberclicks.net/slb-legacy-award>)

1987 – 1989 **AIRC fellowship** to work at the Wistar Institute (Philadelphia, USA)

1989-1997, four bi-annual **NATO travel grants** for a **visiting scientist position** at the Wistar Institute.

### FIELD OF INVESTIGATION

- **Effector functions of myeloid cells and the molecular mechanisms of their regulation**
- **Role of myeloid cells in cancer**

1989- today **Tutor/supervisor** of **at least 50** among students, PhDs and MDs

- “**Reviewer**” of: Science, Nature, Nature Immunology, Science Immunology, Nature Reviews in Immunology, Nature Reviews in Cancer, JCI, JExpMed, BLOOD, Trends in Immunology, Cancer Research, Nature Communications, and more.

- “**Associate Editor**” of Journal of Immunology (2003-2006: 2006-2009)

- “**Section Editor**” of Journal of Leukocyte Biology (2001-present)

- **Member** of the “Editorial Board” of the European Journal of Immunology (2007-2016)

- “**Section Editor**” of Cytokine (2012-present) and **CANCERS** (2020-present)

- “**Guest Associate Editor**” and “**Review Editor**” for **Frontiers in Immunology**

### ORGANIZER of many national and international SCIENTIFIC MEETINGS

#### Five selected PUBLICATIONS (among 240 in PUBMED):

**1 Cell Reports Medicine** 5, 101380, February 20, 2024.

**2 Cancer Immunol Res.** 2023 Sep 11. doi: 10.1158/2326-6066.CIR-23-0239.

**3 Nat Immunol.** 2022 May;23(5):679-691. doi: 10.1038/s41590-022-01189-z.

**4 Sci Immunol.** 2018 Dec 7;3(30):eaat4579. doi: 10.1126/sciimmunol.aat4579.

**5 Cancer Res.** 2018 Jul 1;78(13):3544-3559. doi: 10.1158/0008-5472.CAN-17-2344